The firm’s drug analysis system identifies the unique chemical 'fingerprints' of various substances and can detect the presence of dangerous contaminants such as fentanyl.
CEO Sebastien St-Louis said the Ottawa-based company is seeking “maximum flexibility” to make acquisitions and sign partnerships with players in related industries.